

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **SELECTIVE ATM INHIBITOR SYH2051 OBTAINS CLINICAL TRIAL APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2051 (the “**Product**”) developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product, a Class 1 chemical drug independently developed by the Group, is a selective ATM inhibitor that delays the repairing of DNA double-strand breaks through targeted inhibition of phosphorylation of ATM protein kinase and its downstream signaling proteins CHK2 and KAP1, causing persistent DNA double-strand breaks and ATM-mediated cell cycle arrest to inhibit the proliferation of tumor cells. The indications for this clinical trial approval are solid tumors. The preclinical studies have demonstrated that the Product has good selectivity of ATM targets with excellent in vitro and in vivo activities, providing a promising clinical development value.

By order of the board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 12 June 2023

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*